Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
暂无分享,去创建一个
S. Pignata | N. Colombo | G. Scambia | D. Cibula | E. Braicu | M. Perri | D. Lorusso | F. Zagouri | V. Salutari | J. Frenel | V. Carbone | C. Ricci | L. Musacchio | E. Giudice | V. Ghizzoni | S. Giolitto